Full-Time

Sci II / Senior Scientist

Discovery Gene Therapy Research

Confirmed live in the last 24 hours

Fractyl Health, Inc

Fractyl Health, Inc

51-200 employees

Develops therapies for type 2 diabetes management

Hardware

Senior

Burlington, MA, USA

Requirements
  • PhD in Biology, Biomedical engineering, or other relevant research fields
  • 3-5+ years of highly relevant post-PhD experience in academic or industry environment
  • Extensive experience with mammalian cell culture, DNA transfection, and viral transduction
  • Expertise in DNA construct design for gene therapy expression cassettes
  • Experience in molecular assays quantitating gene expression levels, viral titer, protein activity, etc.
  • Experience with molecular and cellular biology techniques
  • Experience or willingness to work with small and large animal models
  • Track record of challenging oneself to enhance scientific and professional abilities
Responsibilities
  • Contribute to characterizing Fractyl’s lead gene therapy program
  • Pioneer new programs in gene therapy pipeline
  • Design and optimize genetic constructs for therapeutic effect
  • Perform in vitro screening to assess specificity and efficacy
  • Develop and conduct molecular assays to assess specificity, activity, and safety
  • Support generation of biodistribution and transgene expression data
  • Prepare technical reports, summaries, protocols, and analysis of experimental results
  • Maintain an organized electronic lab notebook
  • Identify and bring new technologies to support gene therapy mission
  • Mentor and develop junior research scientists
  • Perform all activities in compliance with regulations and policies
  • Deliver on other assigned responsibilities

Fractyl Health is pioneering Revita, an endoscopic procedural therapy that targets the root causes of type 2 diabetes by remodeling the duodenal lining via hydrothermal ablation. They are also developing Rejuva, a novel pancreatic gene therapy platform aimed at restoring insulin production and islet function in patients with advanced type 2 diabetes.

Company Stage

IPO

Total Funding

$395.4M

Headquarters

Lexington, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

22%

1 year growth

20%

2 year growth

26%